In this week’s VJOncology podcast, we explore recent advances in therapeutic radiopharmaceuticals for metastatic castration-resistant prostate cancer, including emerging alternatives to lutetium-177. Join Jeremie Calais of University of California, Los Angeles, CA, Pedro Barata of Seidman Cancer Center, Cleveland, OH, and Enrique Gallardo of Parc Taulí University Hospital, Barcelona, Spain, as they discuss actinium-225-based PSMA-targeted radioligand therapies, findings from the CONVERGE-01, AcTION, and ProstACT Global trials.